Biogen on Thursday shared news of the subpoena in its annual federal filing. The subpoena seeks information on federal price reporting, rebate payments and Biogen’s co-pay assistance programs for the treatments Tecfidera, Avonex, Tysabri and Plegridy,” according to the report.
The drugmaker increased the U.S. list prices of Tecfidera, Avonex and Plegridy by 8 percent and Tysabri by 3.5 percent. The price hikes went into effect Jan. 1.
The drugnaker said it was cooperating with the investigation, but offered no further details, reports Boston Business Journal.
In December, the company faced backlash after announcing a higher-than-expected price for its new spinal muscular atrophy treatment Spinraza, according to the report.
More articles on supply chain:
5 Trump quotes on drug prices explained
FDA OKs Opdivo for bladder cancer
7 latest FDA approvals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
